Eyeonic Closes Oversubscribed Seed Round, Raising $2.6 Million to Revolutionise Glaucoma Screening
Eyeonic is thrilled to announce the successful closure of our seed round, which was oversubscribed and exceeded our minimum raise target, securing a total of $2.6 million that was co-led by the Goodrich Group, Haines Consulting Group and Kirfield Private Wealth. This significant milestone marks a pivotal step in our journey to transform glaucoma screening through cutting-edge technology.
Eyeonic’s AI-enabled Glaucoma online visual testing delivers diagnostic capability on any computer or tablet, eliminating the need for specialised machines and personnel. Founded by A/Prof Simon Skalicky this breakthrough technology enhances accessibility and affordability, particularly benefiting underserved regions where traditional diagnostic tools are scarce. By integrating advanced AI with innovative design, Eyeonic offers a dynamic, user-friendly solution that redefines medical diagnostics.
This pioneering approach addresses a critical need in eye healthcare, making glaucoma screening more efficient and widespread. Glaucoma is a leading cause of irreversible blindness globally, and early detection is vital to prevent vision loss. Eyeonic’s technology ensures that more patients can be screened accurately and conveniently, advancing medical diagnostics and improving patient outcomes.
Eyeonic’s team, composed of experts with deep expertise in ophthalmology and artificial intelligence, is uniquely positioned to lead this innovation. We are committed to ensuring a brighter future for eye healthcare, and our recent achievements underscore our potential to make a significant impact.
In just six months, Eyeonic has already made remarkable strides. Our technology is now used in 18 countries across four continents, with over 5,000 tests conducted. This rapid adoption demonstrates the global demand for accessible and reliable glaucoma screening solutions.
The funds raised will be instrumental in accelerating our global growth, enhancing our technology, and expanding our reach. We extend our heartfelt thanks to our investors for their confidence and support in Eyeonic’s vision.
We look forward to the continued success of Eyeonic as we work towards revolutionizing glaucoma screening and making a lasting difference in the field of medical diagnostics.
Eyeonic is a MedTech startup revolutionising glaucoma screening with AI-enabled online visual testing. Our innovative technology eliminates the need for specialised machines, enhancing accessibility and affordability for patients worldwide. For more information, visit https://eyeonic.com.au/
